News

January 15, 2019January 15, 2019

Randomized Trials Needed to Assess Benefits of Salmonella Vaccines in SCD Patients, Study Says

News

Randomized controlled trials are needed to examine the benefits of vaccinating people with sickle cell disease (SCD) against salmonella infections, which can be particularly fatal to children with the ... Read more

January 10, 2019January 11, 2019

Crizanlizumab Designated FDA Breakthrough Therapy for Potential in Vaso-occlusive Crisis Prevention

News

Crizanlizumab (SEG101), Novartis‘ investigational compound for sickle cell disease (SCD), received breakthrough therapy designation from the U.S. Food and Drug Administration for its potential to prevent vaso-occlusive crises (VOCs). The FDA ... Read more

January 7, 2019January 8, 2019

CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell Disease

News

The U.S. Food and Drug Administration (FDA) has awarded fast track status to investigational therapy CTX001 to treat sickle cell disease. A Phase 1/2 clinical trial (NCT03745287) is recruiting patients. CTX001 uses the CRISPR gene-editing technology ... Read more

January 3, 2019January 3, 2019

Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study Reports

News

The U.S. opioid epidemic is not linked to higher in-hospital mortality in patients with sickle cell disease (SCD), according to a national study. The study came about due to ... Read more

December 20, 2018December 20, 2018

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

News

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to ... Read more

December 18, 2018December 18, 2018

LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data Reports

News

Bluebird bio presented new positive results from the ongoing Phase 1/2 HGB-206 clinical trial evaluating the effectiveness and safety of investigational gene therapy LentiGlobin in patients with severe sickle cell anemia. ... Read more

December 11, 2018December 11, 2018

Voxelotor Can Promote Long-Term Benefits in Teens, Adults with SCD, Latest Clinical Data Show

News

Global Blood Therapeutics’ lead therapeutic candidate voxelotor can induce rapid, robust, and sustained improvements in the amount of hemoglobin in adolescents and adults with sickle cell disease (SCD), according ... Read more

December 4, 2018December 4, 2018

Delayed Hemolytic Transfusion Reaction Can Lead to Poor Outcome in SCD

News

Hemolytic transfusion reactions, a serious complication of red blood cell transfusion, can be difficult to diagnose in patients with sickle cell disease and even be misinterpreted as severe vaso-occlusive ... Read more

November 27, 2018November 27, 2018

Novartis Announces Funding for Projects Aimed at Supporting Sickle Cell Disease Community

News

For this year’s Solutions to Empower Patients (STEP) program, global healthcare company Novartis has announced it will fund up to five original and creative ideas to help sickle cell ... Read more

November 20, 2018November 20, 2018

New Tool Helps Primary Care Physicians Provide Better Care for SCD Patients, Study Shows

News

A new clinical decision support-based tool can help primary care physicians improve the care and management of patients with sickle cell disease (SCD), a study reports. The study, “Effectiveness of ... Read more

Pin It on Pinterest